Skip to Content
  • Prev Rank
  • Location
    La Jolla, Calif.
  • Industry
  • Sector
    Health Care
  • F1000 Rank
  • G500 Rank
  • Current Streak

This biotechnology firm generates most of its revenue in two ways—by partnering with other pharmaceutical companies, which pay royalties and license fees for use of Ligand’s drugs, and through sales of the company’s “drug reformulation technology,” Captisol. Acquired by Ligand in 2011, Captisol enables the creation of new/improved drugs by improving the solubility, stability and dosing of active pharmaceutical ingredients (to date, six have been approved by the FDA). It also contributed $19 million of the company’s $49 million total revenues last year, and accounted for just over half of 2013 revenue growth. —N.S.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

La Jolla, Calif.
Health Care
Current Streak-

Revenue, Net Income

Revenue Past Four Quarters
Net Income Past Four Quarters12

Growth Rates & Ranks

EPS Growth Rank39
EPS 3 yr Annual Growth Rate Pct66
Revenue Growth Rank38
Rev 3 yr Annual Growth Rate33
Total Return 3 yr Annual Rate73
Total Return Rank
Beat S&P 3 yr Annual Growth Rate?
P/E current fiscal year profits (est.)